The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis

Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis

May 15, 2020 • By Bryn Nelson, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Shidlovski / shutterstock.com

Shidlovski / shutterstock.com

Two new studies delving into the relative safety of biologic drugs prescribed for rheumatoid arthritis (RA) have concluded that real-world applications of abatacept and tumor necrosis factor inhibitors (TNFi’s) are comparable to more conventional therapies in their associated risk of serious infections.

You Might Also Like
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • New Research into Rheumatoid Arthritis, Gout Includes Updates on Methotrexate, Biologics, Ultrasound
  • Rheumatoid Arthritis May Confer Higher Cardiac & Infection Risks
Explore This Issue
May 2020
Also By This Author
  • New Studies Identify Possible Markers of Early Systemic Sclerosis

Triple Therapy

One study, in Arthritis Care & Research, found the risk of serious infection, in­cluding all bacterial and opportunistic infections requiring hospitalization or herpes zoster, wasn’t substantially different between TNFi plus methotrexate (MTX) therapy and triple therapy (MTX, hydroxychloroquine and sulfasalazine).1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The study was led by Seoyoung C. Kim, MD, ScD, MSCE, associate professor of medicine, Harvard Medical School, Boston. “While we still need to discuss other potential adverse events with our patients, at least our data provide real-world evidence on the risk of infection—one of the most common safety events—from the direct comparison,” she says. Dr. Kim is also a member of the Division of Pharmaco­epidemiology and Pharmacoeconomics, and of the Division of Rheumatology, Immunology and Allergy at Brigham and Women’s Hospital, Boston.

Dr. Kim’s cohort study, based on claims data from Truven MarketScan, included 45,208 TNFi plus MTX initiators and 1,387 triple therapy initiators. The study calculated an incidence rate of 2.46 per 100 person-years for any serious infection in the TNFi plus MTX cohort and an incidence rate of 2.03 per 100 person-years in the triple therapy cohort. Using propensity score-based fine stratification and weighting, the researchers calculated a hazards ratio (with a 95% confidence interval) of 1.23 (0.87–1.74) for TNFi plus MTX versus triple therapy for any serious infection.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Abatacept

The second study, published in Arthritis Research & Therapy, found that abatacept was “well tolerated and did not result in an overall increased risk of malignancies, in­fections or autoimmune diseases” compared with other biologic disease-modifying anti-rheumatic drugs (bDMARDs) or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).2

Senior author Kaleb Michaud, PhD, associate professor of immunology and rheumatology, University of Nebraska Medical Center, Omaha and co-director of FORWARD, the National Databank for Rheumatic Diseases, Wichita, Kan., says his team worked on the observational study for more than a decade.

The study reviewed FORWARD-registered RA patients, including 1,496 who initiated abatacept, 3,490 who initiated another bDMARD, and 1,520 who initiated a csDMARD. Based on the hazard ratios, patients on abatacept had a lower risk of hospitalized infections, although the analysis yielded wide confidence intervals in comparisons to other bDMARDs (0.37 [0.18–0.75]) and to csDMARDs (0.31 [0.09–1.05]). The comparisons found no statistically significant difference in the risk of malignancies or psoriasis, albeit again with wide confidence intervals.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Research Reviews, Rheumatoid Arthritis, Safety Tagged With: abatacept, RA Resource Center, triple therapy, tumor necrosis factor inhibitor (TNFi)Issue: May 2020

You Might Also Like:
  • Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
  • New Research into Rheumatoid Arthritis, Gout Includes Updates on Methotrexate, Biologics, Ultrasound
  • Rheumatoid Arthritis May Confer Higher Cardiac & Infection Risks
  • Mechanistic, Epidemiologic Clues Suggest Possible Link Between Obesity, Inflammation in Rheumatoid Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.